Synthesis, characterization and anticonvulsant activity of enaminones. Part 6: Synthesis of substituted vinylic benzamides as potential anticonvulsants

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 11, 1999, Pages 2415-2425

  Foster, James E ^a   Nicholson, Jesse M ^a   Butcher, Raymond ^a   Stables, James P ^b   Edafiogho, Ivan O ^a   Goodwin, Angela M ^a   Henson, Michael C ^a   Smith, Carlynn A ^a   Scott, K R ^a  

^a HOWARD UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Anticonvulsants; Molecular modeling mechanics; NMR; X ray crystal structures

Indexed keywords

3 N (BENZYLAMINO)CYCLOHEX 2 EN 1 ONE; 4 N (BENZYLAMINO) 6 METHYL 2 OXOCYCLOHEX 3 EN 1 OIC ACID; 5,5 DIMETHYL 3 N (BENZAMINO)CYCLOHEX 2 EN 1 ONE; ANTICONVULSIVE AGENT; BENZAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTICONVULSANTS; BENZAMIDES; BENZYLAMINES; CRYSTALLOGRAPHY, X-RAY; ELECTRIC STIMULATION; MALE; MICE; MODELS, MOLECULAR; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0033490799     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(99)00185-6     Document Type: Article

References (35)

1. Coatsworth, J. J. NINDS monograph No. 12, HEW publication no. (NIH) 73-51. U.S. Government Printing Office, 1971.
2. Trimble, M. R. In New Anticonvulsants, Advances in the Treatment of Epilepsy; J. Wiley and Sons: New York, 1994.
3. Carson J.R., Carmosin R.J., Pitis P.M., Vaught J.L., Almond H.R., Stables J.P., Wolf H.H., Swinyard E.A., White H.S. J. Med. Chem. 40:1997;1578.
4. Unverferth K., Engel J., Höfgen N., Rostock A., Günther R., Lankau H.-J., Manzer M., Rolfs A., Liebscher J., Müller B., Hofmann H.-J. J. Med. Chem. 41:1998;63.
5. Edafiogho I.O., Hinko C.N., Chang C., Moore J.A., Mulzac D., Nicholson J.M., Scott K.R. J. Med. Chem. 35:1992;2798.
6. Scott K.R., Edafiogho I.O., Richardson E.L., Farrar V.A., Moore J.A., Tietz E.I., Hinko C.N., Chang H., El-Assadi A., Nicholson J.M. J. Med. Chem. 36:1993;1947.
7. Roberts, R.R.; Edafiogho, I.O.; Scott, K.R. US Patent 5 580 894 1996.
8. Scott K.R., Rankin G.O., Stables J.P., Alexander M.S., Edafiogho I.O., Farrar V.A., Kolen K.R., Moore J.A., Sims L.D., Tonnu A.D. J. Med. Chem. 38:1995;4033.
9. Edafiogho I.O., Moore J.A., Alexander M.S., Scott K.R. J. Pharm. Sci. 83:1994;1155.
10. Laws M.L., Roberts R.R., Nicholson J.M., Butcher R., Stables J.P., Goodwin A.M., Smith C.A., Scott K.R. Bioorganic and Med. Chem. 6:1998;2289.
11. Jones, R. A.; Bean, G. P. The Chemistry of Pyrroles; Academic Press: New York; pp. 284-289.
12. Cook, A. G. Enamines: Synthesis and Reactions; 2nd ed.; Marcel Dekker: New York, 1988; pp.16-17.
13. Edafiogho, I. O.; Scott, K. R. Anticonvulsants, In Burger's Medicinal Chemistry and Drug Discovery; 5th ed.; Wolff, M. E. Ed.; J. Wiley and Sons: New York, 1996; pp. 175-260.
14. Musso D.L., Boswell G.E., Mehta N.B., Soroko F.E., Burchall C.J. Eur. J. Med. Chem. 31:1996;331.
15. Moreau S., Coudert P., Rubat C., Vallee-Goyet D., Gardette D., Gramain J.-C., Couquelet J. Bioorganic and Med. Chem. 6:1998;983.
16. Michon V., Hervé du Penhoat C., Tombret F., Gillardin J.M., Lepage F., Berthon L. Eur. J. Med. Chem. 30:1995;147.
17. Friary R.J., Gilligan J.M., Szajewski R.P., Falci K.F., Franck R.W. J. Org. Chem. 38:1973;3487.
18. Zymalkowski F., Rimek H. Archiv der Pharmazie. 294:1961;759.
19. Kubicki, M.; Codding, P. W. Acta Cryst. 1993, C49, 2045.
20. Spartan SGI Version 4.1.1, Wavefunction, 18401 Von Karman Ave., #370, Irvine, CA 92715. © 1991-1996 Wavefunction.
21. SYBYL, Version 6.04, Tripos Associates, 1699 S. Hanley Road, St. Louis, MO 63144.
22. Anticonvulsant Screening Project, Antiepileptic Drug Development Program, National Institutes of Health, DHEW Publ (NIH) (U.S.) 1978, NIH 78-1093.
23. Porter R.J., Cereghino J.J., Gladding G.D., Hessie B.J., Kupferberg H.J., Scoville B., White B.G. Cleveland Clin. Q. 51:1984;293.
24. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., Swinyard E.A. Epilepsia. 19:1978;400.
25. Piredda S.G., Woodhead J.H., Swinyard E.A. J. Pharmacol. Exp. Ther. 232:1985;741.
26. Free S.M. Jr., Wilson J.W. J. Med. Chem. 7:1964;395.
27. Craig P.N. J. Med. Chem. 14:1971;680.
28. Craig P.N. J. Med. Chem. 15:1972;144.
29. MacLogP Program; version 2.0, BioByte Corp. Claremont, CA 91711.
30. Taft, R. W. In Steric Effects in Organic Chemistry; Newman M. S. Ed. 1956; J. Wiley and Sons: New York; pp. 556-675.
31. Allen F.H., Kennard O. Chem. Design Automation News. 8:1993;31.
32. Rosowsky A., Forsch R.A., Moran R.G. J. Med. Chem. 34:1991;463.
33. Sheldrick, G.M. SelXLTLPC and ShelXTL. Program for crystal structure determination, 1996, Cambridge University, England.
34. Quanta Release 3.2.3, Molecular Simulations Corporation, Waltham, MA 1992.
35. Bigge C.F., Malone T.C., Boxer P.A., Nelson C.B., Ortwine D.F., Schelkun R.M., Retz D.M., Lescosky L.J., Borosky S.A., Vartanian M.G., Schwarz R.D., Campbell G.W., Robichaud L.J., Wätjen F. J. Med. Chem. 38:1995;3720.